The FDA has declined to review Alkermes’ drug for treatment-resistant depression. The agency said it made the decision because of “insufficient evidence of overall effectiveness.” (Endpoints)
A paper that found substantial flaws in CRISPR gene-editing technology has been retracted by its publisher. In a retraction notice, the journal Nature Methods said the study’s design called the results into question. (STAT)
Eli Lilly’s incoming head of R&D plans to get more aggressive in early stage development. Dan Skovronsky said the company will launch more Phase I studies. (Endpoints)
Two U.S. senators are looking into a Florida-based pharma company, which has steadily raised prices for the cancer drug lomustine. The price of the drug from Tri-Source Pharma has jumped more than 1,400% in recent years. (Wall Street Journal)
These ad campaigns are visualizing pain in sophisticated, provocative ways. From dry eyes to arthritis, these six campaigns use visually inventive ways to depict and empathize with patient pain. (MM&M)
